Affinity Wealth Management LLC Buys 174 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Affinity Wealth Management LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,959 shares of the medical research company’s stock after purchasing an additional 174 shares during the quarter. Thermo Fisher Scientific comprises about 0.6% of Affinity Wealth Management LLC’s investment portfolio, making the stock its 23rd largest holding. Affinity Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $1,631,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Van Hulzen Asset Management LLC increased its holdings in shares of Thermo Fisher Scientific by 3.1% in the first quarter. Van Hulzen Asset Management LLC now owns 1,197 shares of the medical research company’s stock worth $328,000 after acquiring an additional 36 shares in the last quarter. Valeo Financial Advisors LLC boosted its position in Thermo Fisher Scientific by 2.0% during the first quarter. Valeo Financial Advisors LLC now owns 1,911 shares of the medical research company’s stock valued at $523,000 after purchasing an additional 38 shares during the last quarter. Community Bank & Trust Waco Texas boosted its position in Thermo Fisher Scientific by 1.8% during the first quarter. Community Bank & Trust Waco Texas now owns 2,366 shares of the medical research company’s stock valued at $648,000 after purchasing an additional 42 shares during the last quarter. Archford Capital Strategies LLC boosted its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Archford Capital Strategies LLC now owns 4,610 shares of the medical research company’s stock valued at $1,032,000 after purchasing an additional 43 shares during the last quarter. Finally, Balasa Dinverno & Foltz LLC boosted its position in Thermo Fisher Scientific by 2.1% during the fourth quarter. Balasa Dinverno & Foltz LLC now owns 2,238 shares of the medical research company’s stock valued at $501,000 after purchasing an additional 46 shares during the last quarter. Institutional investors and hedge funds own 87.89% of the company’s stock.

Shares of NYSE TMO traded up $5.73 during trading hours on Monday, reaching $299.41. 1,640,000 shares of the stock were exchanged, compared to its average volume of 1,632,578. The company has a market cap of $117.47 billion, a price-to-earnings ratio of 26.93, a price-to-earnings-growth ratio of 1.93 and a beta of 1.10. The company has a quick ratio of 1.16, a current ratio of 1.69 and a debt-to-equity ratio of 0.61. Thermo Fisher Scientific Inc. has a 52 week low of $203.90 and a 52 week high of $299.77. The company’s fifty day simple moving average is $276.83.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $2.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.07. The company had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.04 billion. Thermo Fisher Scientific had a return on equity of 17.06% and a net margin of 12.89%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.50 earnings per share. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 12.2 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 16th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.19 per share. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $0.76 dividend on an annualized basis and a yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

In related news, CEO Marc N. Casper sold 50,713 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the sale, the chief executive officer now owns 302,193 shares of the company’s stock, valued at approximately $82,562,149.53. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director C Martin Harris sold 275 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total value of $74,450.75. Following the sale, the director now directly owns 6,433 shares in the company, valued at approximately $1,741,606.09. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,488 shares of company stock worth $14,600,474. Corporate insiders own 0.45% of the company’s stock.

Several research analysts recently commented on the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price target for the company in a research report on Wednesday, June 12th. Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Thursday, May 30th. They set an “outperform” rating for the company. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $315.00 price objective (up from $313.00) on shares of Thermo Fisher Scientific in a research report on Thursday, May 23rd. BTIG Research raised their price objective on Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a research report on Thursday, May 23rd. Finally, UBS Group raised their price objective on Thermo Fisher Scientific from $305.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, May 23rd. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $295.92.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: What impact do institutional investors have on markets?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.